BLTE - Belite Bio - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

921.3M

Cash

88.16M

Avg Qtr Burn

-7.459M

Short % of Float

0.35%

Insider Ownership

60.29%

Institutional Own.

0.81%

Qtr Updated

12/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tinlarebant (LBS-008) Details Dry eye disease , Age-related macular degeneration, Macular degeneration, Geographic atrophy	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tinlarebant (LBS-008) Details Stargardt disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.